Platelets, Cardiac Valves and Sulphinpyrazone - Reply

• References

• 1 Ludlam CA, Allan N, Blandford RB, Dowdle R, Bentley NJ, Bloom AL. Platelet and coagulation function in patients with abnormal cardiac valves treated with Sulphinpyrazone. Thromb Haemostas 1981; 46: 743-746
• 2 Barkhan P. Therapeutic range with BCTR (letter). Thromb Haemostas 1976; 35: 751
• 3 Loeliger EA. The optimal therapeutic range in oral anticoagulation. History and Proposal. Thromb Haemostas 1979; 42: 1141-1152
• 4 Cohn LH, Mudge GH, Pratter F, Collins JJ. Five to eight-year follow-up of patients undergoing porcine heart-valve replacement. N Eng J Med 1981; 304: 258-262
• 5 Dale J, Myhre E. Can acetylsalicytic acid alone prevent arterial thromboembolism?. A Pilot study in patients with aortic ball valve prostheses. Acta Med Scand (Suppl. 645) 1981; 73-78
• 6 Fuster V, Chesebro JH. Systemic thromboemboli in mitral Starr-Edwards prothesis: A longterm followup (10-19 years). Thromb Haemostas (Abstracts) 1981; 46: 288
• 7 Loeliger EA. Sulphinpyrazone and Thromboembolism (letter). Circulation 1981; 64: 1076-1077
• 8 Steele P, Rainwater J. Favourable effect of sulphinpyrazone on thromboembolism in patients with rheumatic heart disease. Circulation 1980; 62: 462-465
• 9 Steele P. Sulphinpyrazone and Thromboembolism (letter). Circulation 1981; 64: 1077
• 10 Goodnight SH. Antiplatelet Therapy for Mitral Stenosis?. Circulation 1980; 62: 466-468
• 11 Schmid FR, Witwer MW, Tesar JT. Acute myelomonocytic leukaemia and multiple myeloma after sulphinpyrazone and colchicine treatment of gout. Br Med J 1976; 3: 89